A Study of ZG005 in Patients With Advanced Solid Tumors - Trial NCT06233292
Access comprehensive clinical trial information for NCT06233292 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd and is currently Recruiting. The study focuses on Solid Tumors. Target enrollment is 484 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Timeline & Enrollment
Phase 1/2
Jun 17, 2022
Jan 01, 2026
Primary Outcome
Dose Limiting Toxicities (DLT),Adverse Event (AE),Objective Response Rate,Maximum tolerated dose (MTD)
Summary
This is a multi-center, open-label, Phase 1/2 study of ZG005 for the treatment of subjects
 with advanced solid tumors, and consists of three stages: dose escalation and confirmation of
 MTD/recommended dose.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06233292
Non-Device Trial